Cargando…

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma

Prognosis remains extremely poor for malignant glioma. Targeted therapeutic approaches, including single agent anti-angiogenic and proteasome inhibition strategies, have not resulted in sustained anti-glioma clinical efficacy. We tested the anti-glioma efficacy of the anti-angiogenic receptor tyrosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lobo, Merryl R., Kukino, Ayaka, Tran, Huong, Schabel, Matthias C., Springer, Charles S., Gillespie, G. Yancey, Grafe, Marjorie R., Woltjer, Randall L., Pike, Martin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672903/ https://www.ncbi.nlm.nih.gov/pubmed/26645398 http://dx.doi.org/10.1371/journal.pone.0144488

Ejemplares similares

Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
por: Lobo, Merryl R., et al.
Publicado: (2014)

Antivascular and antitumor properties of the tubulin-binding chalcone TUB091
por: Canela, María-Dolores, et al.
Publicado: (2016)

Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles
por: Goertz, David E., et al.
Publicado: (2012)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

Antivascular Therapy for Epithelial Ovarian Cancer
por: Duhoux, Francois P., et al.
Publicado: (2010)

Antitumor Effects of Recombinant Antivascular Protein ABRaA-VEGF(121) Combined with IL-12 Gene Therapy
por: Ciomber, Agnieszka, et al.
Publicado: (2013)

HDAC4 Inhibitors as Antivascular Senescence Therapeutics
por: Huang, Chuoji, et al.
Publicado: (2022)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment
por: Sun, Xiaorong, et al.
Publicado: (2015)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer
por: Ma, Xiaocong, et al.
Publicado: (2023)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma
por: D'Souza, Julia C., et al.
Publicado: (2019)

Intravital imaging and cavitation monitoring of antivascular ultrasound in tumor microvasculature
por: Zhao, Xiaoxiao, et al.
Publicado: (2023)

Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray
por: Jiang, Wenhua, et al.
Publicado: (2017)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
por: Stark, Dan P., et al.
Publicado: (2017)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
por: Sassa, Yukio, et al.
Publicado: (2010)

The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy
por: Abu-Yaghi, Nakhleh E., et al.
Publicado: (2012)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
por: Nihei, Yukio, et al.
Publicado: (1999)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Zinc-Substituted Pheophorbide A Is a Safe and Efficient Antivascular Photodynamic Agent
por: Szafraniec, Milena J., et al.
Publicado: (2022)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
por: Suffredini, Dante A., et al.
Publicado: (2018)

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
por: Backen, Alison C., et al.
Publicado: (2018)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Natural food intake patterns have little synchronizing effect on peripheral circadian clocks
por: Xie, Xiaobin, et al.
Publicado: (2020)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
por: Raja, F A, et al.
Publicado: (2011)

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture
por: Jiang, Yanyan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7jf3vc3v3t9j1938cd660ffnl0